Aerinaze

RSS

desloratadine / pseudoephedrine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Aerinaze. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aerinaze.

This EPAR was last updated on 07/12/2022

Authorisation details

Product details
Name
Aerinaze
Agency product number
EMEA/H/C/000772
Active substance
  • desloratadine
  • pseudophedrine sulfate
International non-proprietary name (INN) or common name
  • desloratadine
  • pseudoephedrine
Therapeutic area (MeSH)
Rhinitis, Allergic, Seasonal
Anatomical therapeutic chemical (ATC) code
R01BA52
Publication details
Marketing-authorisation holder
N.V. Organon
Revision
22
Date of issue of marketing authorisation valid throughout the European Union
30/07/2007
Contact address

Kloosterstraat 6
5349 AB, Oss
Netherlands

Product information

07/12/2022 Aerinaze - EMEA/H/C/000772 - IAIN/0046

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Nasal preparations

Therapeutic indication

Symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion.

Assessment history

How useful was this page?

Add your rating
Average
3 ratings
2 ratings
1 rating